Race Oncology (ASX:RAC) has announced it has secured a new patent on its cancer drug, bisantrene, from the US Patent and Trademarks Office (USPTO).
The company said the patent is the fourth for bisantrene in the US.
“The new US patent allows additional claims around the use of bisantrene that improve the therapeutic benefit of bisantrene and related chemical structures”, said Race CSO Dr Daniel Tillett.
The company said the new patent addresses the expanded therapeutic utility of bisantrene (and related chemical structures), in particular, methods and compositions for improving the therapeutic efficacy of bisantrene and reducing side effects.
Race said the new patent (US 10,548,876) builds on bisantrene patents granted in the US in 2018 and 2019 (US 9,993,460, US 9,974,774, and US 10,500,192) and further strengthens its IP position for bisantrene.